Evidence mapPaperPMID 40062355Full record

ReviewPathogens & immunity2025

A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.

Christoph Lange, Graham Bothamley, Gunar Günther, Lorenzo Guglielmetti, Irina Kontsevaya, Liga Kuksa, Berit Lange, Natalie Lorent, Francesca Saluzzo, Martina Sester and 4 more

Abstract readReview
In one paragraph

Review in Pathogens & immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Christoph LangeInfectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
Graham BothamleyHomerton University Hospital, London, United Kingdom.
Gunar GüntherDepartment of Pulmonology, Allergology and Clinical Immunology, Inselspital Bern, Bern University Hospital, Bern, Switzerland.
Lorenzo GuglielmettiSorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France.
Irina KontsevayaDepartment of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.
Liga KuksaTuberculosis and Lung Disease clinic, Riga East University hospital, Riga, Latvia.
Berit LangeDepartment of Epidemiology, Helmholtz Centre for Infection Research.
Natalie LorentDepartment of Respiratory Diseases, University Hospital Leuven, Leuven, Belgium.
Francesca SaluzzoIRCCS San Raffaele Scientific Institute, Milan, Italy.
Martina SesterDepartment of Transplant and Infection Immunology.
Marc TebrueggeDepartment of Child and Adolescent Medicine & Austrian National Reference Centre for Childhood Tuberculosis, Klinik Ottakring, Vienna Healthcare Group, Vienna, Austria.
Simone TunesiInfectious Diseases Unit, AOU SS Antonio e Biagio e C. Arrigo, Alessandria, Italy.
Conor TweedMRC Clinical Trials Unit, University College London, London, United Kingdom.
Tuberculosis Network European Trials group (TBnet)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the field of tuberculosis and non-tuberculous mycobacterial (NTM) disease we are looking back on an exciting year 2024 with more than 10,000 publications listed in PubMed. Methods: Our aim, to review the scientific literature of the year 2024, is challenged by the enormous number of publications. Therefore, if your article is not included or your favorite field of mycobacteriology not covered, please forgive us. Our "Year in Review" is very much clinically oriented with lesser emphasis on basic science, microbiology, and biotechnology. Results: Members of the steering committee of the Tuberculosis Network European Trials group (TBnet; www.tbnet.eu) report on 139 publications in the fields of epidemiology, prevention, diagnosis, and treatment of tuberculosis and NTM diseases published in 2024 that we found particularly important. We report publications separately for tuberculosis in children and adults and for NTM disease and provide a brief overview of newer technologies in the diagnostic pipeline. Furthermore, we summarize priorities for tuberculosis and NTM disease research, development, and implementation, all of which represent the perspective of our combined clinical experience. Conclusions: This Year in Review provides a concise summary of the clinically relevant highlights of the published literature in tuberculosis and NTM diseases in 2024.

Indexed as

NTMpediatric TBTBTBnet

Identifiers

PMID40062355
PMCPMC11888605

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.